Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche
The novel compounds are in late pre-clinical development. They show a considerably improved side effect profile compared to non-selective NMDA receptor antagonists and include structures with good oral availability.
Dr Kemp, CEO of Evotec Neurosciences AG, commented: "We are delighted to have acquired the license to this broad portfolio of patents covering both injectable and orally active NMDA receptor NR2B subtype selective antagonists. They broaden our CNS portfolio significantly, supplementing our Alzheimer's collaboration with Takeda and a number of promising internal programmes. Recent pre-clinical and clinical data has shown that while these subtype selective compounds retain the therapeutic potential of non-selective NMDA receptor antagonists, they are much less prone to adverse side-effects."
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.